Healthcare / Medical Instruments & SuppliesShenzhen
$9.65
-0.33 (-3.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $456.8M · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.1B
P/E
21.9x
↑EV/EBITDA
10.2x
↓ROE
6.9%
↑Gross Margin
28.6%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.5%
FCF CAGR
-15.3%
FCF margin
12.4%
FCF / Net income
1.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.67B · net income $248.9M · FCF $456.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.67B | $3.67B | $3.33B | $2.76B | $4.21B |
| Net Income | $248.9M | $248.9M | $368.7M | $110.4M | $406.8M |
| EBITDA | $569.4M | $569.4M | $708.9M | $428.3M | $713.6M |
| EPS | 0.40 | 0.40 | 0.59 | 0.17 | 0.64 |
| Gross Margin | 28.6% | 28.6% | 28.8% | 27.9% | 33.6% |
| Operating Margin | 16.2% | 16.2% | 14.8% | 11.8% | 20.8% |
| Net Margin | 6.8% | 6.8% | 11.1% | 4.0% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.19 | 0.30 | 0.30 |
| Current Ratio | 1.84 | 1.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $456.8M | $456.8M | $554.6M | $137.0M | $751.7M |
| Returns | |||||
| ROE | 6.9% | 6.9% | 10.7% | 3.5% | 13.1% |
| Valuation | |||||
| P/E | 21.93 | 21.93 | 14.31 | 55.24 | 18.82 |
| EV/EBITDA | 10.21 | 10.21 | 7.55 | 15.55 | 11.30 |
| P/B | 1.66 | 1.66 | 1.53 | 1.91 | 2.47 |
| Growth & Yield | |||||
| Revenue Growth | 10.4% | 10.4% | 20.7% | -34.5% | — |
| EPS Growth | -31.8% | -31.8% | 247.0% | -73.5% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.6%
EPS terminal req.
$0.86
Spread vs growth
-60.5%
5Y implied EPS CAGR
20.8%
EPS terminal req.
$1.04
Spread vs growth
-52.7%
10Y implied EPS CAGR
15.3%
EPS terminal req.
$1.67
Spread vs growth
-47.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.8%
Start / end P/E
15.0x → 24.0x
EPS bridge
0.59 → 0.40
Residual
-19.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.